How Heart Specialists Benefit From Medicare’s TAVR Restrictions

Why It Matters

Removing the CED would streamline TAVR access, cut delays and associated mortality, and challenge the financial model that specialty societies have built around Medicare’s coverage rules.

Key Takeaways

• Medicare’s TAVR CED limits access for seniors with aortic stenosis
• STS and ACC set surgeon fees at 62.5% of cardiologist rates
• Registry fees cost hospitals about $9 million annually nationwide
• Data shows volume requirements no longer predict TAVR outcomes
• Delays add 59 days to treatment, raising mortality and costs

Pulse Analysis

The transcatheter aortic valve replacement (TAVR) has become the standard of care for patients over 75 with severe aortic stenosis, yet Medicare has kept the procedure under a Coverage with Evidence Development (CED) policy for 14 years. The CED framework forces beneficiaries to enroll in the Society of Thoracic Surgeons‑American College of Cardiology (STS‑ACC) TVT registry and obliges hospitals to meet surgeon‑and‑procedure volume thresholds. Critics argue that the Society of Thoracic Surgeons and the American College of Cardiology helped shape these requirements to protect surgical revenue, turning a clinical tool into a bureaucratic gate.

The financial burden of the CED is substantial. Setting up the TVT registry costs roughly $25,000 per site, with an additional $10,500 annual fee, translating to about $9 million a year across the 860 qualified hospitals. Smaller community and rural centers often cannot absorb these expenses, concentrating TAVR services in high‑volume academic hubs. Moreover, the mandated surgeon‑presence fee—62.5 % of the interventionalist’s rate—creates a parallel revenue stream for thoracic surgeons. Recent analyses of registry data show that procedural volume no longer correlates with outcomes, undermining the original justification for these requirements.

CMS is slated to issue a coverage decision by June 15, and a repeal of the CED could unlock faster, more equitable access for millions of seniors. Eliminating the registry mandate would likely shave the average 59‑day treatment delay, reducing the 50 % higher three‑year mortality observed in late‑treated patients and saving roughly $37,000 per case in downstream costs. The move also threatens the financial streams of the STS and ACC, prompting a clash between specialty societies’ fiscal interests and Medicare’s mandate to deliver evidence‑based care. The outcome will set a precedent for how Medicare evaluates emerging technologies.